Key GI Journal Articles - Colorectal - Metastatic - anti VEGF/Double Biologics
Published: Fri Apr 29, 2011 Updated:Fri Dec 9, 2011
-
Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
NC Tebbutt et al, JCO. Jul 1 2010; 28(19):3191-98
-
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J Hecht et al, JCO. Feb 10 2009; 27(5):1408-17
-
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
J Tol et al, NEJM. Feb 05 2009; 360(6):563-72
-
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
LB Saltz et al, JCO. Apr 20 2008; 26(12):2013-9
-
Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study
L Saltz et al, JCO. Oct 10 2007; 25 (29):4557-61
-
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
BJ Giantonio et al, JCO. Apr 20 2007; 25(12):1539-44
-
Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer
FF Kabbinavar et al, JCO. Jun 1 2005; 23(16):3706-12
-
Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer
HI Hurwitz et al, JCO. May 20 2005; 23(15):3502-8
-
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
H Hurwitz et al, NEJM. Jun 3 2004; 350(23):2335-42
